Alex Dahmani

Director of Business Development • Adaptive Biotechnologies

Alex Dahmani has degrees in Genetics, Immunology, and Business.  His academic research focused on human T cell activity using an advanced humanized mouse model.  Prior to working at Adaptive Biotechnologies, he worked for Columbia Technology Ventures where he helped review and commercialize new technologies invented on campus.  He also started a remote patient monitoring company called Quio Technologies.  At Adaptive, he works with biotech and pharma partners who use Adaptive’s immune medicine platform to discover and develop novel immunotherapies for infectious disease, autoimmunity, and oncology.  

Also Speaking

Rob Tressler

Chief Scientific Officer • Excellos

Will Rohleder

Development Director • Reef Group

Lung-I Cheng

Vice President, Cell and Gene Therapy • AmerisourceBergen

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.